A PYMNTS Company

Denmark: Pharmaceutical giant slams EU fine as unreasonable

By  |  June 13, 2013

Danish pharmaceutical giant Lundbeck, which is one of several companies fined by the European Commission after an industry-wide probe, is slamming the regulator for fining the company on what it deems unreasonable grounds. The Commission raided Lundbeck offices in 2005 and then fined the company for making anticompetitive agreements with other pharmaceutical companies that barred them from producing generic forms of ones of Lundbeck’s most popular drugs. While the company claims those agreements were legal, and that it had the right to make those contracts while key patent lawsuits were being decided, the European Commission is fighting pharmaceutical companies against such so-called pay-for-delay schemes. Lundbeck is currently speaking out against the regulator for fining the company and modifying its accusations after the company sent a statement of objections concerning the Commission’s ruling.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    Subscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Full Content: European Voice

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.